Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Jacqualyn A. Fouse Sells 7,791 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Jacqualyn A. Fouse sold 7,791 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total transaction of $214,642.05. Following the sale, the director now directly owns 137,396 shares of the company’s stock, valued at approximately $3,785,259.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Agios Pharmaceuticals Trading Up 2.3 %

NASDAQ AGIO opened at $30.63 on Friday. The company has a fifty day simple moving average of $28.95 and a 200 day simple moving average of $24.82. Agios Pharmaceuticals, Inc. has a 12-month low of $19.80 and a 12-month high of $35.50. The company has a market cap of $1.72 billion, a P/E ratio of -4.83 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.64) by ($0.08). Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative return on equity of 38.08%. The business had revenue of $7.10 million during the quarter, compared to analyst estimates of $7.80 million. During the same period in the previous year, the business posted $0.67 EPS. The business’s revenue for the quarter was up 65.1% compared to the same quarter last year. Sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -5.28 EPS for the current year.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. lifted its stake in Agios Pharmaceuticals by 9.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,587 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 387 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in Agios Pharmaceuticals by 2.2% during the 1st quarter. Great West Life Assurance Co. Can now owns 25,483 shares of the biopharmaceutical company’s stock valued at $586,000 after acquiring an additional 550 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Agios Pharmaceuticals by 1.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 47,604 shares of the biopharmaceutical company’s stock valued at $1,348,000 after acquiring an additional 590 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Agios Pharmaceuticals by 1.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,497 shares of the biopharmaceutical company’s stock valued at $928,000 after acquiring an additional 689 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Agios Pharmaceuticals by 96.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,429 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 700 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Tuesday. JPMorgan Chase & Co. reduced their price objective on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating for the company in a research report on Friday, February 23rd. Finally, Royal Bank of Canada reduced their price objective on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $33.50.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.